{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:40:18Z","timestamp":1791027618760,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,10]],"date-time":"2019-11-10T00:00:00Z","timestamp":1573344000000},"content-version":"vor","delay-in-days":2261,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1093\/annonc\/mdt181","type":"journal-article","created":{"date-parts":[[2013,5,28]],"date-time":"2013-05-28T00:19:39Z","timestamp":1369700379000},"page":"2434-2438","source":"Crossref","is-referenced-by-count":21,"title":["Significant efficacy of 2-chlorodeoxyadenosine\u00b1 rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up"],"prefix":"10.1016","volume":"24","author":[{"given":"G.","family":"Cervetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pelosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ghio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Cecconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt181_bb0010","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1046\/j.1365-2141.1996.d01-1711.x","article-title":"Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hematologie Cellulaire (GFHC)","volume":"93","author":"Troussard","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdt181_bb0015","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.1999.17.8.2486","article-title":"Marginal zone B cell lymphoma: a clinical comparison of nodal and mucosa associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project","volume":"17","author":"Nathwani","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt181_bb0020","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1182\/blood.V95.6.1950","article-title":"Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients","volume":"95","author":"Berger","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt181_bb0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(03)00981-1","article-title":"Splenic marginal-zone lymphoma: a distinct clinical and pathological entity","volume":"4","author":"Thieblemont","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt181_bb0030","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/1097-0142(20010115)91:2<294::AID-CNCR1001>3.0.CO;2-W","article-title":"Splenectomy influences bone marrow infiltration in patients with splenic marginal zone lymphoma with or without villous lymphocytes","volume":"91","author":"Franco","year":"2001","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt181_bb0035","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1046\/j.1365-2141.2003.04449.x","article-title":"Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes","volume":"122","author":"Andouin","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdt181_bb0040","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood.V100.5.1648.h81702001648_1648_1654","article-title":"Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients","volume":"100","author":"Chacon","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt181_bb0045","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","article-title":"Splenic marginal zone lymphoma: a prognostic model for clinical use","volume":"107","author":"Arcaini","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt181_bb0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection","volume":"347","author":"Hermine","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt181_bb0055","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/sj.leu.2403443","article-title":"Response to antiviral treatment in hepatitis C virus associated marginal zone lymphomas","volume":"18","author":"Keladi","year":"2004","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdt181_bb0060","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1046\/j.1365-2141.1997.3523168.x","article-title":"Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes","volume":"99","author":"Bolam","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdt181_bb0065","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/sj.leu.2401710","article-title":"Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes","volume":"14","author":"Lefrere","year":"2000","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdt181_bb0070","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1600-0609.2005.00426.x","article-title":"Deoxycoformycin (penttostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes","volume":"75","author":"Iannitto","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1093\/annonc\/mdt181_bb0075","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1365-2141.1998.0636f.x","article-title":"Splenic lymphoma with villous lymphocytes (SLVL) responding to 2-chlorodeoxyadenosine (2-chlorodeoxyadenosine)","volume":"100","author":"Virchis","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdt181_bb0080","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/10428190009054887","article-title":"Lack of efficacy of 2-chlorodeoxyadenosine in the treatment of splenic lymphoma with villous lymphocytes","volume":"40","author":"Lefrere","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdt181_bb0085","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/hon.717","article-title":"Low dose 2-chlorodeoxyadenosine schedule activity in splenic marginal zone lymphomas","volume":"21","author":"Riccioni","year":"2003","journal-title":"Hematol Oncol"},{"key":"10.1093\/annonc\/mdt181_bb0090","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3816\/CLM.2004.n.005","article-title":"Combination of rituximab, cyclophosphamide and vincristine induces complete hematologic remission of splenic marginal zone lymphoma","volume":"4","author":"Arcaini","year":"2004","journal-title":"Clin Lymphoma"},{"key":"10.1093\/annonc\/mdt181_bb0095","first-page":"856","article-title":"Rituximab monotherapy for splenic marginal zone lymphoma","volume":"90","author":"Bennett","year":"2005","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdt181_bb0100","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cncr.21931","article-title":"Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with Rituximab with or without chemotherapy or chemotherapy alone","volume":"107","author":"Tsimberidou","year":"2006","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt181_bb0105","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3816\/CLM.2006.n.033","article-title":"Activity of rituximab in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia","volume":"6","author":"Fabbri","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1093\/annonc\/mdt181_bb0110","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0145-2126(99)00110-1","article-title":"An advantageous method to evaluate IgH rearrangement and its role in minimal residual disease detection","volume":"23","author":"Galimberti","year":"1999","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdt181_bb0115","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.seminhematol.2010.01.004","article-title":"Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab","volume":"47","author":"Bennet","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1093\/annonc\/mdt181_bb0120","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/hon.820","article-title":"Rituximab monotherapy is higly effective in splenic marginal zone lymphoma","volume":"25","author":"Kalpadakis","year":"2007","journal-title":"Hematol Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdt181_bb0125","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.leukres.2009.04.003","article-title":"2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma","volume":"34","author":"Orciuolo","year":"2010","journal-title":"Leuk Res"},{"issue":"4","key":"10.1093\/annonc\/mdt181_bb0130","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/annonc\/mdp395","article-title":"Significant efficay of 2-chlorodeoxyadenosine with or without Rituximab in the treatment of splenic marginal zone lymphoma (SMZL)","volume":"21","author":"Cervetti","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt181_bb0135","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2141.2008.07333.x","article-title":"Rituximab as treatment of minimal residual disease in hairy cell leukaemia: extended follow-up","volume":"143","author":"Cervetti","year":"2008","journal-title":"Br J Haemat"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419369285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419369285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/9\/2434\/518455\/mdt181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:42:17Z","timestamp":1624693337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419369285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0923753419369285"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt181","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}